The purpose of this study was to assess the value of high-sensitivity CRP in a homogenous population of patients with first STEMI undergoing primary PCI and guideline-based therapies for predicting the risk of: (i) LVSD at 6 months after hospital discharge (LVSD6M), which was the primary study endpoint; and (ii) the need for hospitalization for HF in patients with LVSD6M in long-term multi-year follow-up, which was the secondary study endpoint. This evidence concerns the gene CRP and hydrops fetalis.